SIGA Technologies, Inc. Stock price

Equities

SIGA

US8269171067

Pharmaceuticals

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
8.56 USD +0.71% Intraday chart for SIGA Technologies, Inc. -4.04% +52.86%
Sales 2024 * 191M Sales 2025 * 169M Capitalization 604M
Net income 2024 * 84M Net income 2025 * 78M EV / Sales 2024 * 2.3 x
Net cash position 2024 * 167M Net cash position 2025 * 192M EV / Sales 2025 * 2.43 x
P/E ratio 2024 *
6.97 x
P/E ratio 2025 *
7.14 x
Employees 45
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.48%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.71%
1 week-2.39%
Current month+64.30%
1 month+59.40%
3 months+54.79%
6 months+66.86%
Current year+52.86%
More quotes
1 week
7.86
Extreme 7.855
8.93
1 month
4.75
Extreme 4.75
8.98
Current year
4.26
Extreme 4.26
8.98
1 year
4.22
Extreme 4.215
8.98
3 years
4.22
Extreme 4.215
26.99
5 years
3.96
Extreme 3.96
26.99
10 years
0.20
Extreme 0.2
26.99
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 Jan. 26
Director of Finance/CFO 53 11-02-09
Chief Operating Officer - 97-12-31
Members of the board TitleAgeSince
Director/Board Member 71 09-03-10
Director/Board Member 70 20-06-15
Director/Board Member 53 22-11-09
More insiders
Date Price Change Volume
24-03-28 8.56 +0.71% 1,231,921
24-03-27 8.5 +2.16% 802,329
24-03-26 8.32 -0.36% 926,266
24-03-25 8.35 -4.68% 1,052,219
24-03-22 8.76 -1.79% 1,251,010

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock
  2. Equities
  3. Stock SIGA Technologies, Inc. - Nasdaq